TL-118—anti-angiogenic treatment in pancreatic cancer: a case report

@article{Breuer2013TL118antiangiogenicTI,
  title={TL-118—anti-angiogenic treatment in pancreatic cancer: a case report},
  author={Shani Breuer and Ofra Maimon and L. Appelbaum and T. Peretz and A. Hubert},
  journal={Medical Oncology},
  year={2013},
  volume={30},
  pages={1-4}
}
  • Shani Breuer, Ofra Maimon, +2 authors A. Hubert
  • Published 2013
  • Medicine
  • Medical Oncology
  • Pancreatic cancer is one of the most aggressive malignant tumors. In recent years, little progress has been made in understanding and treatment of the disease. The two most commonly used chemotherapy drugs approved for the treatment of pancreatic cancer are gemcitabine and fluorouracil. Anti-angiogenic treatment is one of the current promising approaches in cancer translational research. Its aim is to inhibit development of new blood vessels and thereby prevent further tumor growth. We present… CONTINUE READING
    7 Citations
    Clinical decision support system as a risk assessment tool to aid in earlier diagnosis of pancreatic cancer
    • PDF
    Estimation of Tumor Size Evolution Using Particle Filters
    • 4
    • PDF

    References

    SHOWING 1-10 OF 18 REFERENCES
    Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice
    • 13
    • PDF
    Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
    • 1,514
    • PDF
    Angiogenesis and hepatic colorectal metastases.
    • 9
    • PDF
    Pancreatic Cancer
    • 4,519
    • PDF
    Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy
    • 53
    Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    • 3,351
    • PDF
    Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
    • 678
    Cimetidine inhibits angiogenesis and suppresses tumor growth.
    • 29